Changes in CD69, CD25 and HLA-DR expressions in peripheral blood T cells in Kawasaki disease

Changes in CD69, CD25 and HLA-DR expressions in peripheral blood T cells in Kawasaki disease

OBJECTIVE: The study was designed to investigate the changes in CD(69), CD(25) and HLA-DR expressions in peripheral blood T cell in Kawasaki disease (KD)

Bibliographische Detailangaben
Veröffentlicht in:Zhonghua er ke za zhi = Chinese journal of pediatrics. - 1960. - 44(2006), 5 vom: 19. Mai, Seite 329-32
1. Verfasser: Zhang, Yi-ying (VerfasserIn)
Weitere Verfasser: Huang, Xian-mei, Kang, Man-li, Gong, Fang-qi, Qian, Bai-qin
Format: Aufsatz
Sprache:Chinese
Veröffentlicht: 2006
Zugriff auf das übergeordnete Werk:Zhonghua er ke za zhi = Chinese journal of pediatrics
Schlagworte:English Abstract Journal Article Antigens, CD Antigens, Differentiation, T-Lymphocyte Biomarkers CD69 antigen Glucocorticoids HLA-DR Antigens Immunoglobulins, Intravenous Immunologic Factors mehr... Interleukin-2 Receptor alpha Subunit Lectins, C-Type Platelet Aggregation Inhibitors Aspirin R16CO5Y76E Methylprednisolone X4W7ZR7023
LEADER 01000caa a22002652 4500
001 NLM163567611
003 DE-627
005 20250207095619.0
007 tu
008 231223s2006 xx ||||| 00| ||chi c
028 5 2 |a pubmed25n0545.xml 
035 |a (DE-627)NLM163567611 
035 |a (NLM)16780706 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Zhang, Yi-ying  |e verfasserin  |4 aut 
245 1 0 |a Changes in CD69, CD25 and HLA-DR expressions in peripheral blood T cells in Kawasaki disease 
264 1 |c 2006 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 20.07.2010 
500 |a Date Revised 07.06.2016 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a OBJECTIVE: The study was designed to investigate the changes in CD(69), CD(25) and HLA-DR expressions in peripheral blood T cell in Kawasaki disease (KD) 
520 |a METHODS: The authors detected CD(69), CD(25) and HLA-DR expressions in peripheral blood T cell by using flow cytometry. The patients who met the diagnostic criteria for KD comprised sixteen boys and fifteen girls (4 - 60 months of age; mean, 26 +/- 18 months). All received intravenous gammaglobulin at a dose of 1 g/(kg.d), for 2 days and oral aspirin at a dose of 30 - 50 mg/(kg.d). In case of persistent fever, a repeated dose of intravenous gammaglobulin or I.V. methylprednisolone at a dose of 20 mg/(kg.d) for three daily doses was attempted. The authors tested blood samples from 17 healthy controls consisting of nine boys and eight girls (3 - 84 months of age; mean, 25 +/- 18 months) and the samples from 31 patients 
520 |a RESULTS: The percentage of peripheral blood CD(3)(+) T lymphocyte was (54.4 +/- 9.0)% in acute stage of KD and (65.0 +/- 7.0)% in healthy controls. There was a significant difference between the two groups (P < 0.001). The values of CD(69)(+) [(11.2 +/- 12.6)%, vs. (0.6 +/- 0.4)%], CD(25)(+) [(9.2 +/- 3.5)% vs. (3.9 +/- 1.8)%] and HLA-DR(+) [(8.3 +/- 5.0)% vs. (4.3 +/- 2.3)%] in KD patients were markedly increased compared to those of the healthy controls. After intravenous gammaglobulin treatment, the percentage of CD(3)(+)CD(69)(+) and CD(3)(+)CD(25)(+) significantly decreased [CD(3)(+)CD(69)(+): (14.0 +/- 13.0)% vs. (1.6 +/- 1.2)%, P < 0.05; CD(3)(+)CD(25)(+): (7.8 +/- 4.1)% vs. (2.0 +/- 0.6)%, P < 0.01]. However, the CD(3)(+) T lymphocytes increased [(50.8 +/- 5.0)% vs. (64.9 +/- 5.5)%, P < 0.01]. There was no significant difference in expression of CD(3)(+) T lymphocyte cell activating markers between coronary artery disease group and normal coronary artery group in KD cases (P > 0.05) 
520 |a CONCLUSION: CD(3)(+) T cell activation in the early and middle stages is involved in the mechanism responsible for cardiovascular injury 
650 4 |a English Abstract 
650 4 |a Journal Article 
650 7 |a Antigens, CD  |2 NLM 
650 7 |a Antigens, Differentiation, T-Lymphocyte  |2 NLM 
650 7 |a Biomarkers  |2 NLM 
650 7 |a CD69 antigen  |2 NLM 
650 7 |a Glucocorticoids  |2 NLM 
650 7 |a HLA-DR Antigens  |2 NLM 
650 7 |a Immunoglobulins, Intravenous  |2 NLM 
650 7 |a Immunologic Factors  |2 NLM 
650 7 |a Interleukin-2 Receptor alpha Subunit  |2 NLM 
650 7 |a Lectins, C-Type  |2 NLM 
650 7 |a Platelet Aggregation Inhibitors  |2 NLM 
650 7 |a Aspirin  |2 NLM 
650 7 |a R16CO5Y76E  |2 NLM 
650 7 |a Methylprednisolone  |2 NLM 
650 7 |a X4W7ZR7023  |2 NLM 
700 1 |a Huang, Xian-mei  |e verfasserin  |4 aut 
700 1 |a Kang, Man-li  |e verfasserin  |4 aut 
700 1 |a Gong, Fang-qi  |e verfasserin  |4 aut 
700 1 |a Qian, Bai-qin  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhonghua er ke za zhi = Chinese journal of pediatrics  |d 1960  |g 44(2006), 5 vom: 19. Mai, Seite 329-32  |w (DE-627)NLM136249191  |x 0578-1310  |7 nnns 
773 1 8 |g volume:44  |g year:2006  |g number:5  |g day:19  |g month:05  |g pages:329-32 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_50 
912 |a GBV_ILN_61 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_130 
912 |a GBV_ILN_227 
912 |a GBV_ILN_244 
912 |a GBV_ILN_285 
912 |a GBV_ILN_294 
912 |a GBV_ILN_350 
912 |a GBV_ILN_665 
912 |a GBV_ILN_813 
951 |a AR 
952 |d 44  |j 2006  |e 5  |b 19  |c 05  |h 329-32